Moreover, the blood levels of MUC1 mRNA during treatment were significantly increased in patients with tumor response of PD, whereas the patients who achieved a PR had a significant decrease in blood MUC1 mRNA levels, implying that the changes of MUC1 mRNA levels in the course of treatment with gefitinib may predict imaging response to treatment. Here, MUC1 is linked to neoplasm.